AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19821938 — intervention group
Group type: EXPERIMENTAL
Intervention: AV delay determined by electrogram-based SmartDelay
Number of subjects: 950
Study 19821938 — intervention group
Group type: EXPERIMENTAL
Intervention: AV delay determined by echocardiography (mitral inflow)
Number of subjects: 950
Study 19821938 — intervention group
Group type: COMPARATOR
Intervention: Fixed AV delay (120 ms)
Number of subjects: 950
Study 18390085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (10 mg) administered for 12 hours without oxytocin (group I)
Number of subjects: 106
Study 18390085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (10 mg) with oxytocin (group II)
Number of subjects: 106
Study 18390085 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg) with oxytocin (group III)
Number of subjects: 106
Study 18390085 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment)
Number of subjects: 106
Study 16630553 — intervention group
Group type: EXPERIMENTAL
Intervention: Random cohort with LPL gene mutations
Number of subjects: 0
Study 16630553 — intervention group
Group type: COMPARATOR
Intervention: Patient cohort with LPL P207L deficiency
Number of subjects: 0
Study 15012730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐deamino‐8‐D‐arginine vasopressin (dDAVP) administration
Number of subjects: 14
Study 15012730 — intervention group
Group type: EXPERIMENTAL
Intervention: Water loading and water deprivation
Number of subjects: 14
Study 11023260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant‐supported overdentures
Number of subjects: 102
Study 11023260 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 102
Study 8993091 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of sertraline to ongoing treatment
Number of subjects: 33
Study 8993091 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone augmentation
Number of subjects: 33
Study 8993091 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine dose increase
Number of subjects: 33
Study 1447653 — intervention group
Group type: EXPERIMENTAL
Intervention: Odorant identification test using five selected odorants (baby powder, bubble gum, candy cane, fish, orange)
Number of subjects: 175
Study 1447653 — intervention group
Group type: EXPERIMENTAL
Intervention: Odorant identification test
Number of subjects: 175
Study 6546829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 48
Study 6546829 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 48
Study 30834850 — intervention group
Group type: EXPERIMENTAL
Intervention: Table (nutrition table with information on energy and main nutrients per 100 g)
Number of subjects: 780
Study 30834850 — intervention group
Group type: EXPERIMENTAL
Intervention: Label (healthy choice label for the healthier product)
Number of subjects: 780
Study 30834850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (nutrition table and healthy choice label)
Number of subjects: 780
Study 30834850 — intervention group
Group type: COMPARATOR
Intervention: Control (picture of the FOP presented)
Number of subjects: 780
Study 30096878 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g/day blackberries (BB, 1500 mg/day flavonoids)
Number of subjects: 27
Study 30096878 — intervention group
Group type: COMPARATOR
Intervention: Calorie and carbohydrate matched amount of gelatin (GEL, flavonoid-free control)
Number of subjects: 27
Study 26808688 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 10 mg
Number of subjects: 0
Study 26808688 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg
Number of subjects: 0
Study 25461786 — intervention group
Group type: EXPERIMENTAL
Intervention: Student Bodies™+ (SB+) intervention
Number of subjects: 126
Study 25461786 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 126
Study 21887804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufang Danshen capsule 1000 mg twice-daily
Number of subjects: 55
Study 21887804 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 55
Study 19020291 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (9 mg/kg)
Number of subjects: 10
Study 19020291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (2,000 mg)
Number of subjects: 10
Study 19020291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18021136 — intervention group
Group type: EXPERIMENTAL
Intervention: APN-provided prenatal care
Number of subjects: 85
Study 18021136 — intervention group
Group type: COMPARATOR
Intervention: Physician-provided prenatal care (control)
Number of subjects: 85
Study 14756855 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg or 50 mg daily for 10 days, starting 5 days before menstrual flow.
Number of subjects: 14
Study 11191041 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drumming
Number of subjects: 111
Study 11191041 — intervention group
Group type: COMPARATOR
Intervention: Control (resting and listening)
Number of subjects: 111
Study 9990419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.05% cream
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.1% cream
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.01% gel
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.1% gel microsphere
Number of subjects: 55
Study 9990419 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 55
Study 8071051 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg I/mL iopromide
Number of subjects: 150
Study 8071051 — intervention group
Group type: COMPARATOR
Intervention: 160 mg I/mL ioversol
Number of subjects: 150
Study 8071051 — intervention group
Group type: COMPARATOR
Intervention: 128 mg I/mL iopamidol
Number of subjects: 150
Study 3068828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated double-velours grafts
Number of subjects: 224
Study 3068828 — intervention group
Group type: COMPARATOR
Intervention: Non-gelatine-impregnated double-velours grafts
Number of subjects: 224
Study 3068828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated grafts without velours trimming (Cooley II, Meadox)
Number of subjects: 224
Study 3068828 — intervention group
Group type: COMPARATOR
Intervention: Non-gelatine-impregnated grafts without velours trimming (Cooley II, Meadox)
Number of subjects: 224
Study 3068828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated grafts manufactured by a new warp-knitting procedure (Protegraft 2000, B. Braun AG)
Number of subjects: 224
Study 3068828 — intervention group
Group type: COMPARATOR
Intervention: Non-gelatine-impregnated grafts manufactured by a new warp-knitting procedure (Protegraft 2000, B. Braun AG)
Number of subjects: 224
Study 3068828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated grafts (B. Braun AG)
Number of subjects: 224
Study 3068828 — intervention group
Group type: COMPARATOR
Intervention: Non-gelatine-impregnated grafts (B. Braun AG)
Number of subjects: 224
Study 30064815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual X-ray absorptiometry body composition data
Number of subjects: 123
Study 30064815 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue
Number of subjects: 123
Study 30064815 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 123
Study 28758822 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored nurse navigation intervention
Number of subjects: 50
Study 28758822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 25468459 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 160
Study 25468459 — intervention group
Group type: COMPARATOR
Intervention: Pringle maneuver (PM)
Number of subjects: 160
Study 22999066 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (30 g alcohol/d)
Number of subjects: 67
Study 22999066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 67
Study 22999066 — intervention group
Group type: EXPERIMENTAL
Intervention: Gin (30 g alcohol/d)
Number of subjects: 67
Study 22999066 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 67
Study 22185253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel-2 (FR-2) appliance
Number of subjects: 0
Study 22185253 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 19287043 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 44
Study 19287043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 triplicate predose ECGs
Number of subjects: 44
Study 19287043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 triplicate predose ECG
Number of subjects: 44
Study 19287043 — intervention group
Group type: EXPERIMENTAL
Intervention: Day ‐1 time‐matched baseline ECGs
Number of subjects: 44
Study 19287043 — intervention group
Group type: EXPERIMENTAL
Intervention: No baseline correction
Number of subjects: 44
Study 19287043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16705560 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing counseling session
Number of subjects: 131
Study 16291444 — intervention group
Group type: COMPARATOR
Intervention: No manipulation
Number of subjects: 20
Study 16291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical hemolysis via a 27-gauge needle
Number of subjects: 20
Study 16291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of potassium acetate (KAc)
Number of subjects: 20
Study 16291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of KAc and mechanical hemolysis
Number of subjects: 20
Study 16291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction factor for K+
Number of subjects: 20
Study 16291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the correction factor with 500 mg/dL of p‐Hgb
Number of subjects: 20
Study 12077012 — intervention group
Group type: COMPARATOR
Intervention: Post-exercise (31)P‐MRS indices of muscle oxidative metabolism in DM and PM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: COMPARATOR
Intervention: Phosphocreatine and adenosine diphosphate recovery half-times in DM and PM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: COMPARATOR
Intervention: Maximum rate of mitochondrial ATP production in DM and PM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of proton efflux from muscle fibres in DM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of proton efflux from muscle fibres in PM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: COMPARATOR
Intervention: MRS-detectable abnormalities in DM and PM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: COMPARATOR
Intervention: Correlation between MRS-detectable abnormalities and degree of inflammation or fatty infiltration of the muscle
Number of subjects: 9
Study 12077012 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo findings in DM and PM patients
Number of subjects: 9
Study 12077012 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal mitochondria seen in muscle biopsies of DM and PM patients
Number of subjects: 9
Study 10780258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg)
Number of subjects: 8
Study 10780258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (12 mg and 50 mg)
Number of subjects: 8
Study 10780258 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (0 mg)
Number of subjects: 8
Study 7828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic (NH) intervention plus chlorthalidone
Number of subjects: 844
Study 7828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic (NH) intervention plus acebutolol
Number of subjects: 844
Study 7828296 — intervention group
Group type: COMPARATOR
Intervention: Nutritional-hygienic (NH) intervention only
Number of subjects: 844
Study 7828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic (NH) intervention plus doxazosin mesylate
Number of subjects: 844
Study 7828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic (NH) intervention plus amlodipine maleate
Number of subjects: 844
Study 7828296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic (NH) intervention plus enalapril maleate
Number of subjects: 844
Study 2240382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid)
Number of subjects: 32
Study 2240382 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (3 g linoleic acid)
Number of subjects: 32
Study 2240382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 32
Study 2240382 — intervention group
Group type: COMPARATOR
Intervention: Fish oil and Corn oil
Number of subjects: 32
Study 337220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia procedure
Number of subjects: 0
Study 30389377 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention
Number of subjects: 136
Study 30389377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 29083219 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-PAM (6 MI calls including SHSe feedback)
Number of subjects: 339
Study 29083219 — intervention group
Group type: COMPARATOR
Intervention: PAM (6 contact control calls)
Number of subjects: 339
Study 25733632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index (HGI) meal (GI92)
Number of subjects: 10
Study 25733632 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic index (LGI) meal (GI37)
Number of subjects: 10
Study 23135605 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvinorin A (0.375-21 μg/kg)
Number of subjects: 8
Study 23135605 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvinorin A
Number of subjects: 8
Study 21751253 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin/mineral
Number of subjects: 198
Study 19821969 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 137
Study 16464327 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients recruited by GPs
Number of subjects: 166
Study 16464327 — intervention group
Group type: COMPARATOR
Intervention: Patients recruited by advertisement
Number of subjects: 166
Study 15238454 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 120
Study 15238454 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 120
Study 11743506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg once daily
Number of subjects: 474
Study 11743506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 9565416 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (8 microg/kg birth weight per day)
Number of subjects: 200
Study 9565416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8168332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ouabain
Number of subjects: 0
Study 2908528 — intervention group
Group type: EXPERIMENTAL
Intervention: KC8702 (new method vaccine)
Number of subjects: 0
Study 2908528 — intervention group
Group type: COMPARATOR
Intervention: 21A (conventional vaccine)
Number of subjects: 0
Study 31186619 — intervention group
Group type: EXPERIMENTAL
Intervention: 2800 ppm dentifrice
Number of subjects: 60
Study 31186619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm dentifrice
Number of subjects: 60
Study 31186619 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 60
Study 29231610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needling therapy applied after ovulation and at the end of the premenstrual stage.
Number of subjects: 68
Study 29231610 — intervention group
Group type: COMPARATOR
Intervention: Regular sequential therapy of acupuncture (control group).
Number of subjects: 68
Study 25262192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin
Number of subjects: 72
Study 25262192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin and intradermal injection of lidocaine
Number of subjects: 72
Study 25262192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 23008027 — intervention group
Group type: EXPERIMENTAL
Intervention: Acridine orange therapy
Number of subjects: 170
Study 23008027 — intervention group
Group type: COMPARATOR
Intervention: Conventional wide-margin resection
Number of subjects: 170
Study 21684389 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiocomputer-delivered tailored feedback intervention
Number of subjects: 566
Study 21684389 — intervention group
Group type: COMPARATOR
Intervention: No intervention (identical assessment without feedback)
Number of subjects: 566
Study 21684389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in self-perceived HIV risk (for women)
Number of subjects: 566
Study 21684389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in self-perceived HIV risk (for men)
Number of subjects: 566
Study 21684389 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported HIV risk
Number of subjects: 566
Study 18377149 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal confidence in care‐recipient recovery
Number of subjects: 109
Study 18377149 — intervention group
Group type: COMPARATOR
Intervention: Functional Limitations Profile
Number of subjects: 109
Study 17138198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (40 mug fentanyl, 10-minute infusion/lockout, up to 6 doses/h)
Number of subjects: 799
Study 17138198 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (1-mg morphine bolus, 5-minute lockout, up to 10 mg/h)
Number of subjects: 799
Study 17138198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system
Number of subjects: 799
Study 17138198 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia
Number of subjects: 799
Study 12775315 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 983
Study 12775315 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 983
Study 12775315 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 983
Study 10703677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (ivID) protocol, 100 mg loading doses for 2 weeks followed by 25 to 150 mg weekly for 6 months, targeting TSAT between 30 and 50%.
Number of subjects: 42
Study 10703677 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving ivID doses of 25 to 150 mg/week for 6 months, targeting TSAT of 20 to 30%.
Number of subjects: 42
Study 9200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery alone
Number of subjects: 0
Study 9200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrated movement
Number of subjects: 0
Study 9200247 — intervention group
Group type: COMPARATOR
Intervention: Guided movement
Number of subjects: 0
Study 1546065 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52021 pretreatment in FU group
Number of subjects: 12
Study 1546065 — intervention group
Group type: COMPARATOR
Intervention: No intervention in RU group
Number of subjects: 12
Study 3890032 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic extensive surgery or radiotherapy on the initial tumor volume
Number of subjects: 81
Study 3890032 — intervention group
Group type: COMPARATOR
Intervention: Combined chemotherapy using vincristine, dactinomycin, adriamycin, cyclophosphamide until maximum tumor reduction, followed by radiotherapy or surgery on the residual mass only
Number of subjects: 81
Study 31107579 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia
Number of subjects: 213
Study 31107579 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prandial distress syndrome
Number of subjects: 213
Study 31107579 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilia in the second part of duodenum
Number of subjects: 213
Study 29886815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Jump-Based Aquatic Exercise (HIIAE) program, 24 weeks, 30 minutes per session
Number of subjects: 25
Study 27906653 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer left ventricular electric delay (QLV)
Number of subjects: 426
Study 27906653 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer QLV (≥median)
Number of subjects: 426
Study 24296814 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (AtDCS)
Number of subjects: 16
Study 24296814 — intervention group
Group type: COMPARATOR
Intervention: Placebo transcranial direct current stimulation (PtDCS)
Number of subjects: 16
Study 22417382 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 81
Study 22417382 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifiers (HH)
Number of subjects: 81
Study 20700733 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing of numbers (small vs large)
Number of subjects: 0
Study 20700733 — intervention group
Group type: COMPARATOR
Intervention: Writing of letters
Number of subjects: 0
Study 18402095 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer and bond (3M Scotch Bond)
Number of subjects: 78
Study 18402095 — intervention group
Group type: COMPARATOR
Intervention: No primer and bond
Number of subjects: 78
Study 16521640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell anemia patients
Number of subjects: 25
Study 12450951 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable-good premorbid functioning group
Number of subjects: 535